Marisa Sharkey
Senior Vice President, Investor Relations and TreasuryBurlington Stores
FounderView Profile →Global Head of Life Sciences · Blackstone
Nicholas Galakatos is global head of life sciences at Blackstone and chairs the business’s investment committees. He joined through Blackstone’s acquisition of Clarus in December 2018. His background combines chemistry research, pharmaceutical operations and healthcare investing.
Last reviewed: Oct 21, 2026
Global Head of Life Sciences Blackstone
Last Reviewed: October 21, 2026
Nicholas Galakatos is global head of life sciences at Blackstone and chairs the business’s investment committees. He joined through Blackstone’s acquisition of Clarus in December 2018. His background combines chemistry research, pharmaceutical operations and healthcare investing.
Galakatos trained in organic chemistry and conducted postdoctoral work at Harvard Medical School before building an industry and investment career in healthcare. From 1997 to 2000, he was vice president of new business and a management team member at Millennium Pharmaceuticals.
He later became a general partner at MPM Capital and co-founded Clarus in 2005, serving as managing director. His company-building work included founding roles at Millennium Predictive Medicine, Millennium Biotherapeutics, TransForm Pharmaceuticals and Anthos Therapeutics. He was founding CEO and chairman of TransForm.
Blackstone acquired Clarus in December 2018, bringing him into the firm to lead life sciences. His investment experience spans biotechnology, pharmaceutical partnerships and diagnostics. He also serves as a director of Neurvati and BioMed Realty and a trustee of Reed College.
Galakatos earned his undergraduate degree at Reed College and a PhD in organic chemistry at MIT. He subsequently conducted postdoctoral studies at Harvard Medical School; that work is not an additional degree.